Results 191 to 200 of about 556,852 (338)

Iatrogenic Alterations of Immunologic Surveillance in Man and Their Influence on Malignancy [PDF]

open access: yes, 1971
Agosin M.   +85 more
core   +1 more source

Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor

open access: green, 2011
Cristina R. Antonescu   +5 more
openalex   +2 more sources

Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing.
Andrew M. Brandon   +13 more
wiley   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Distraction Osteogenesis Reconstruction Following Resection of Bone Sarcomas [PDF]

open access: green
Anthony Bozzo   +4 more
openalex   +1 more source

Kaposi Sarcoma

open access: yesMedicine, 1993
R W, Martin, A F, Hood, E R, Farmer
openaire   +2 more sources

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy